Posted by Michael Wonder on 02 Jan 2017
Bronchial carcinoma: additional use of crizotinib not seen
2 January 2017 - The dossier does not contain any suitable data for patients with ROS1 positive non-small-cell lung cancer.
Crizotinib (Xalkori) has been available since August 2016 for the treatment of adult patients with advanced ROS1 positive non-small cell lung cancer. In an early benefit assessment, the Institute for Quality and Efficiency in Health Care (IQWiG) has examined whether this medicine has advantages over appropriate comparator therapies.
An additional benefit is not established: for one patient group, the dossier does not contain any data, and the data for another two patient groups are not suitable for evaluation.
